Mario Liste-Hermoso
- Oncology top 5%
- Cancer Research top 10%
- Pulmonary and Respiratory Medicine
- Immunology
- Molecular Biology
- Co-authors
- Carlos H. BarriosShilpen PatelJane Yuet Ching HuiAnh Nguyen DucKyung Hae JungShigehira SajiNadia HarbeckRoberto Hegg
- Topics
- Breast Cancer Treatment Studies (4 papers)Cancer Immunotherapy and Biomarkers (3 papers)Cancer Treatment and Pharmacology (3 papers)
- Cited by
- OncologyCancer ResearchImmunology
- Partner nations
- United StatesSwitzerlandJapan
In The Last Decade
Mario Liste-Hermoso
7 papers receiving 751 citations
Hit Papers
Peers
Comparison fields: 5 of 55
- Oncology 633
- Cancer Research 298
- Pulmonary and Respiratory Medicine 192
- Immunology 181
- Molecular Biology 88
Countries citing papers authored by Mario Liste-Hermoso
This map shows the geographic impact of Mario Liste-Hermoso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Liste-Hermoso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Liste-Hermoso more than expected).
Fields of papers citing papers by Mario Liste-Hermoso
This network shows the impact of papers produced by Mario Liste-Hermoso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Liste-Hermoso. The network helps show where Mario Liste-Hermoso may publish in the future.
Co-authorship network of co-authors of Mario Liste-Hermoso
This figure shows the co-authorship network connecting the top 25 collaborators of Mario Liste-Hermoso. A scholar is included among the top collaborators of Mario Liste-Hermoso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Liste-Hermoso. Mario Liste-Hermoso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 12 | |
| 2 | 8 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 14 | |
| 7 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialbreakdown → | 718 |
About Mario Liste-Hermoso
Mario Liste-Hermoso is a scholar working on Cancer Research, Oncology and Reproductive Medicine, having authored 7 papers that have together received 756 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (4 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (633 citations), Cancer Research (298 citations) and Immunology (181 citations). Mario Liste-Hermoso has collaborated with scholars based in United States, Switzerland and Japan. Frequent co-authors include Carlos H. Barrios, Shilpen Patel, Jane Yuet Ching Hui, Anh Nguyen Duc, Kyung Hae Jung, Shigehira Saji, Nadia Harbeck, Roberto Hegg, Vidya Maiya and Melinda L. Telli. Their work appears in journals such as The Lancet, Cancer Research and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.